The FSP’s 47th Annual Pathology Conference: Updates and Practical Approaches in Pathology will be held for the first-time ever as a virtual conference on February 12-14, 2021. Going virtual will allow us to educate our members as well as the larger pathology community on the latest scientific developments in pathology, while ensuring our attendees, faculty members, and supporters are staying safe and healthy from the comfort of their homes. The conference will provide pathologists with education surrounding a wide range of topics and the opportunity to learn and adopt new strategies and tools to aid in the diagnosis and analysis of diseases. Specific topics being covered include pearls and pitfalls in gastrointestinal pathology, breast pathology and genitourinary pathology.
Registration to the Virtual Conference Includes:
Accessing the Virtual Platform
Attendees will receive an email from our virtual platform on Monday February 8, 2021 with specific instructions on how to log in and access the virtual platform. If you do not receive your email with information to log in by February 10, 2021, please contact us at email@example.com.
The FSP will be communicating with attendees through email and through social media to provide updates on the virtual conference, so please be sure to check your email regularly and follow us on social media!
Associate Professor, Department of Pathology and Laboratory Medicine
University of Miami Miller School of Medicine
Topic: COVID-19 Roundtable Discussion on Testing and Treatment with Live Q&A
M.R. Abell Professor of Surgical Pathology
Department of Pathology and Clinical Laboratories
University of Michigan
Ann Arbor, MI
Topic: GI Pathology
Director of Breast Pathology and Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor of Clinical Pathology and Laboratory Medicine
Weill Cornell Medical College
New York City, NY 10065
Topic: Breast Pathology
Senior Associate Consultant
Mayo Clinic Florida
Topic: Liposarcoma and its Mimics
Professor of Pathology, Urology, Oncology
Johns Hopkins Medicine
Topic: GU Pathology
Topic: COVID-19 and its Effects on Blood Banking and Transfusion Medicine
Immediate Past President
Florida Medical Association
President and CEO
Fort Lauderdale, FL
College of American Pathologists
CEO and Laboratory Director
Southeastern Pathology Associates
Southeast Georgia Regional Medical Center
Topic: CAP Update: Advancing Pathology Through Advocacy and Laboratory/Member Programs
Department of Pathology, Immunology, and Laboratory Medicine
University of Florida
Topic: COVID-19 Roundtable Discussion on Testing and Treatment with Live Q&A
Consultant and Assistant Professor
Mayo Clinic Florida
Topic: Adult Diffuse Gliomas: An Update on Classification
Associate Professor of Pathology
Mayo Clinic Florida
Topic: Practical Guide to Biliary Diseases of the Liver
Professor of Pathology
University of Miami
Topic: A Wry View of Gastritis and Gastric Neuroendocrine Tumors
Chair and Professor, Pathology and Laboratory Medicine
Mayo Clinic and Foundation
Topic: Mayo Clinic Laboratory (MCL) Outreach
Florida Medical Association
Professor of Laboratory Medicine and Pathology
Chair, Division of Clinical Microbiology
Topic: COVID-19 Roundtable Discussion on Testing and Treatment with Live Q&A
Friday, February 12
3:15 pm - 4:00 pm
Understanding Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Evolving molecular Insights & Diagnosis of an Aggressive Hematologic Malignancy
This session is sponsored by Stemline Therapeutics
Patricia Moody, MD
Saturday, February 13
8:00 am - 9:00 am
Recent Updates on Biomarker Testing Recommendations in Resectable NSCLC and Ovarian Cancer
This session is sponsored by AstraZeneca
Shirley Michelle Shiller, DO, MSPT
Co-Director, Medical Genetics, Staff Pathologist
Baylor Sammons Cancer Center
Baylor University Medical Center
Molecular Testing in Resectable NSCLC
Homologous Recombination Testing (HRD) in Advanced Ovarian Cancer
Sunday, February 14
11:30 am - 12:15 pm
Diagnostic Solutions: Ventana HER2 Dual ISH Probe Cocktail
This session is sponsord by Roche Diagnostics
Horacio Ramirez, PhD
Pathology Solutions Specialist
1700 Epcot Resorts Blvd
Orlando, FL 32830
Room Rate: $329/night (plus tax)
Reserve your hotel room by clicking here. You can also call the Disney group reservations line at 407-939-4686 and mention the FSP rate to reserve your room. The group rate is available until January 20, 2021. Any reservations made after this date will be subject to availability.
About Disney’s Yacht & Beach Club
Delight in the formal grace of a grand New England-style yacht club at this lakeside hotel. Relax in the inviting elegance of a plush lobby replete with nautical touches, explore the whimsical Stormalong Bay and rent a variety of watercraft from Bayside Marina. Sharing many amenities with its pastel-toned sister, Disney’s Beach Club Resort, Disney’s Yacht Club Resort is walking distance to Epcot and a convenient boat ride to Disney’s Hollywood Studios.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.
The Florida Medical Association designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CRITERIA FOR SUCCESS
Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme. If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by Wednesday, February 24, 2021.
This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.
STATEMENT OF NEED
The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.
At the conclusion of this activity, all participants should be able to:
At the time of this printing, full commercial support information was not available. All commercial support will be communicated to attendees in advance of the meeting.
Join us for the 47th Annual Pathology Conference taking place virtually for the first-time ever on February 14-16, 2021. Going virtual will allow us to educate our members on the latest scientific developments in pathology, while ensuring our attendees, faculty members, and supporters are staying safe and healthy from the comfort of their homes. Our virtual conference will provide many additional benefits to our sponsors that a live conference cannot offer, including:
We thank you in advance for enabling us, through your support, to deliver our conference virtually so that we may continue to provide invaluable education to our attendees.
Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.
Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients.
Caris Life Sciences ® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (https://castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions on the risk of sentinel lymph node positivity and the intensity of follow-up, surveillance imaging, referral and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and sentinel lymph node status and is supported by consistent evidence in over 25 publications including two meta-analyses showing Level 1A evidence classification.
DecisionDx® DiffDx-Melanoma is a new gene expression profile test designed to reduce diagnostic uncertainty by providing a highly accurate and objective evaluation. DiffDx-Melanoma adds diagnostic clarity leading to a more confident diagnosis and a clearer treatment path for patients.
DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.
Change Healthcare partners with providers, payers, and consumers to reduce costs, create efficiencies, and effectively manage complex workflows. Together we are accelerating the journey toward improved lives and healthier communities. We also help pathology practices and labs increase cash flow, patient revenue, and coding and compliance with our billing, collection, and revenue cycle management services.
Cleveland Clinic Laboratories is dedicated to providing high-quality, clinically impactful pathology and laboratory diagnostic services combined with readily available consultation from experienced pathologists and laboratory scientists. Our laboratories offer excellence in coagulation, flow cytometry, hematopathology, molecular testing and cytogenomics, and microbiology as well as subspecialty services in anatomic pathology. This approach ensures that every specimen submitted will be evaluated by a pathologist with a high level of diagnostic expertise in that specific field of pathology.
CSI Laboratories is a leading cancer testing and diagnostics laboratory trusted by pathologists, oncologists, and community hospitals throughout the U.S. For more than 22 years, we've been at the forefront of advanced testing methods, using a collaborative approach to manage testing with speed, precision and care, and delivering testing that is medically necessary and clinicaly significant. CSI provides a full complement of cancer testing, including Flow, Cytogenics, FISH, IHC, and Molecular services. Our national cancer testing laboaratory has one mission: Keeping our clients and their patients at the forefront of everything we do.
ELITechGroup has been in operation for over 50 years and distributes to over 100 countries. Proud to be the World Leader in Aerospray staining technology and Cytocentrifugation, offering the world's most reliable solutions in performance and reliability. ELITechGroup is confident that this automated technology will elevate the performance of any laboratory and facilitate superior results.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.
Interpace Diagnostics is a leading provider of molecular testing for thyroid and pancreatic cancer. The Company offers ThyGeNEXT® and ThyraMIR®, a unique approach that combines a mutation panel with a microRNA classifier for Thyroid cancer. These tests, utilizing the Markers That Matter™, have been fully validated with a demonstrated NPV of 97% and PPV of 75%. Also available are PancraGEN® and PanDNA®, which help in stratifying cancer risk of pancreatic cysts or biliary strictures. By integrating a proprietary combination of tumor suppressor genes and loss of heterozygosity with imaging, chemistries, and other first line testing, a risk classification is determined to help inform the best course of action, from surgery to active surveillance.
MagMutual is a provider of Medical Malpractice insurance and practice solutions, including patient safety services to over 25,000 physicians and hospitals.
MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.
NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore.
PIMS Inc. was incorporated in 1998 and has evolved into a full-service Medical Billing and Practice Management Services company. PIMS provides comprehensive billing and consulting services for providers of all sizes. In addition, PIMS offers an innovative and robust laboratory information system designed specifically for the anatomic pathology practice in mind.
Roche Diagnostics is one of the world’s leaders in medical diagnostic instrument and reagent systems providing leading-edge automation for use in the diagnosis of cancer and infectious disease.
We are building awareness around Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an aggressive and deadly blood cancer that often presents with skin lesions. Historically, the average time to diagnosis is 6 months, and following diagnosis the median overall survival is approximately 8 to 14 months. An early and accurate diagnosis is critical in improving patient outcomes, which is why it is important to include CD123, CD4, and CD56 in your hematologic diagnostic panel. THINK CD123456!
Vachette is a pathology laboratory consulting firm. We specialize in revenue cycle auditing, reworking revenue cycle processes, and negotiating managed care contracts. Our three-tiered process of revenue strategy, revenue management, and revenue insurance helps our clients find millions of dollars in lost revenue each year. Imagine having a professional team assess your revenue cycle process. How would your billing team perform? We audit over $1 billion in medical billings annually. Isn't it time to see how you score?
The Florida Society of Pathologists (FSP) Poster Review Committee invites the submission of posters for inclusion in the Virtual Poster Hall during the FSP’s Annual Pathology Conference taking place virtually on February 12-14, 2021. The purpose of the FSP Poster Hall is to stimulate research, provide a venue to share innovative and effective educational programs, showcase unique research projects, and to encourage networking among pathologists. All pathologists are invited to submit case-based posters or research-based posters for inclusion in the Virtual Poster Hall. Residents and fellows are eligible to compete in the FSP Poster Competition.
Poster Submission Deadline
January 8, 2021
5:00 pm EST
Residents and fellows who are enrolled in a full-time approved training program in pathology or sub-specialty of pathology in the state of Florida are invited to submit and are eligible to participate in the FSP Poster Competition.
Poster Competition Presentation Process and Awards
Posters will be pre-judged and selected by FSP judges based on quality, innovation, approach/design, and visuals. Posters will be judged twice and are subject to an additional preliminary review to determine eligibility. If judges deem that changes need to be made for posters to be eligible for presentation, lead authors will be contacted by email. The first judging will be done before the conference, and it will be a blind review. The second judging will be conducted during the live poster sessions during the virtual conference. The scores from both judging sessions will be combined to determine the winners. The first-place winner will receive $500, the second-place winner will receive $250, and the third-place winner will receive $150.
To be considered for the Poster Competition and awards, you must:
Winners of the Poster Competition will be announced, and prizes will be awarded during the FSP Business Meeting on Sunday, February 14, 2021.
Poster Submission Instructions
Please read through the submission instructions below before preparing your poster:
General Information and Policies:
Poster entries can only be accepted electronically and must adhere to the following guidelines:
You will be asked for the following:
The online poster submission does not allow you to save and return to resume later. Therefore, before starting your submission, have all materials and information ready. After the poster is submitted, you will receive an automated email to confirm your submission. If you do not receive the email within 24 hours, please contact the FSP office at firstname.lastname@example.org or call Erin Corrales at 904-309-6204.
The poster must relate to an appropriate topic in the field of pathology. Poster authors will be required to indicate which topic BEST matches the content of their poster. Topics are:
Please note, you will be required to use the pre-approved poster template for your poster submission. To download the templates click on the links below:
Resident/Fellow Platform Presentations
Residents and fellows are invited to submit their poster to be considered for an oral podium presentation during a designated session on the conference agenda. If you wish to be considered for an oral podium presentation, you can indicate this on the conference registration form. If selected for an oral podium presentation, you must commit to presenting at the conference and will be contacted by the FSP with further details on the virtual presentation format. Please note this is a separate event from the Poster Competition and residents and fellows will still be required to present their poster as part of this competition to be eligible for the Poster Competition awards.
The FSP will not be responsible for submissions not received via the website or for submission errors caused by Internet service outages, hardware or software delays, power outages, or unforeseen events. Faxed, emailed or mailed hard-copy posters or posters sent on a CD/disc WILL NOT be accepted. If you have questions, please contact the FSP office at email@example.com or call 904-309-6204.
The FSP is excited to be able to offer the following valuable networking and career-building opportunity to our pathologists in training attendees.
The FSP will host a virtual fellowship fair for residents to meet virtually with the coveted fellowship programs in Florida. This is a unique opportunity for our resident attendees to learn about the pathology fellowship programs available in our wonderful state, to gain advice on the application and interview process and to connect one-on-one with program representatives.
Each fellowship program will have a resource page on the FSP virtual platform containing presentations, videos, and resources available for residents to view on-demand at any time during the virtual conference. Attendees will be able to meet with the program representatives through Zoom meetings to connect and ask questions. The FSP virtual platform will be open on the first day of the FSP meeting on February 12 and will continue to be available to all attendees for 60 days after the meeting allowing attendees the opportunity to continue to view the resources available from the fellowship programs.
This event is open to medical students, residents and fellows attending the FSP virtual conference and is complimentary.
Pathologists in Training Roundtable
The FSP will host a virtual roundtable event for pathologists in training covering issues of major significance to residents transitioning from residency to fellowship to practice. During the roundtable event, attendees will participate in intimate and interactive Zoom meetings with roundtable leaders who will cover a different topic of interest. Roundtable leaders will rotate to each group of attendees to share their insight and wisdom. Our Roundtable leaders will consist of FSP board members and prominent pathology thought leaders representing the various fields of pathology practice and specialties including clinical, laboratory, hospital based and academic.
This event is open to medical students, residents and fellows attending the FSP meeting and is complimentary.
FSP Member Login